VJOncology is committed to improving our service to you

ESMO 2020 | ACTIVE trial update: EGFRm NSCLC

VJOncology is committed to improving our service to you

Byoung Chul Cho

Byoung Chul Cho, MD, PhD, Yonsei Cancer Center, Seoul, Korea, discusses updates on the ACTIVE (NCT02824458) multicentered, randomized, double-blind, placebo-controlled phase III trial, comparing the use of apatinib plus gefitinib versus placebo plus gefitinib as first-line treatment for advanced epidermal growth factor receptor-mutant (EGFRm) non-small-cell lung cancer (NSCLC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter